Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00103714
Status:
COMPLETED
Last Update Posted:
2015-10-20
First Post:
2005-02-14
Brief Title:
Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Multi-Center Double-Blind Randomized Placebo-Controlled 28-Day Study of Denufosol Tetrasodium INS37217 Inhalation Solution in Patients With Cystic Fibrosis Lung Disease
Status:
COMPLETED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objectives of this study are to evaluate the safety tolerability and preliminary efficacy of two dose levels of INS37217 denufosol tetrasodium Inhalation Solution in patients with cystic fibrosis CF lung disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None